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 2009 Wiley-LissABSTRACT: A quasi-equilibrium mass transport analysis has been developed to quantitatively
explain the solubility–permeability interplay that exists when using cyclodextrins as pharma-
ceutical solubilizers. The model considers the effects of cyclodextrins on the membrane perme-
ability (Pm) as well as the unstirred water layer (UWL) permeability (Paq), to predict the overall
effective permeability (Peff) dependence on cyclodextrin concentration (CCD). The analysis
reveals that: (1) UWL permeability markedly increases with increasing CCD since the effective
UWL thickness quickly decreases with increasing CCD; (2) membrane permeability decreases
with increasing CCD, as a result of the decrease in the free fraction of drug; and (3) since Paq
increases and Pm decreases with increasing CCD, the UWL is effectively eliminated and the
overall Peff tends toward membrane control, that is, PeffPm above a critical CCD. Application of
this transport model enabled excellent quantitative prediction of progesterone Peff as a function
of HPbCD concentrations in PAMPA assay, Caco-2 transepithelial studies, and in situ rat
jejunal-perfusion model. This work demonstrates that when using cyclodextrins as pharma-
ceutical solubilizers, a trade-off exists between solubility increase and permeability
decrease that must not be overlooked; the transport model presented here can aid in striking
the appropriate solubility–permeability balance in order to achieve optimal overall absorption.
 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:2739–2749, 2010Keywords: low-solubility drugs; cyclodextrins; solubility–permeability interplay; drug
transport analysis; intestinal absorptionINTRODUCTION
Modern drug discovery techniques (e.g., advances in
high throughput screening methods, the introduction
of combinatorial chemistry) have resulted in an
increase in the number of drug candidates being
selected that exhibit low solubility in water. By some
estimates, more than 40% of new drug candidates
are lipophilic and have poor aqueous solubility.1–3
With very minor exceptions, dissolution of the drug
substance in the aqueous gastrointestinal (GI)
milieu is a prerequisite for absorption following oral
administration. Hence, compounds with inadequate
aqueous solubility often suffer from limited oral
bioavailability. A great challenge facing the pharma-and Jonathan M. Miller contributed equally to this
ce to: Gordon L. Amidon (Telephone: 734-764-2226;
82; E-mail: glamidon@umich.edu)
aceutical Sciences, Vol. 99, 2739–2749 (2010)
, Inc. and the American Pharmacists Association
JOURNceutical scientist is to formulate these molecules into
orally administered dosage forms with sufficient
bioavailability.4,5
Among the various approaches to improve the
aqueous solubility of lipophilic drugs, the utilization
of cyclodextrins has become widespread in recent
years.6,7 Cyclodextrins are crystalline, nonhygro-
scopic, cyclic oligosaccharides, with a hydrophilic
outer surface and a less hydrophilic central cavity
which is able to host hydrophobic solutes. From a
drug delivery standpoint, cyclodextrins have gained
extensive attention and use, due to their ability to
increase the solubility of hydrophobic drugs via
the formation of more water soluble inclusion
complexes.8,9
According to the Biopharmaceutics Classification
System (BCS),10 the extent of oral absorption of a
drug is governed by two primary factors: (1) the
effective permeability across the intestinal mucosa
and (2) the solubility and dissolution characteristics
in the GI milieu.11–13 While increased solubility of a
lipophilic drug can be achieved by a cyclodextrinsAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 6, JUNE 2010 2739
2740 DAHAN ET AL.based delivery system, the effect of such a formulation
on the apparent permeability is not completely
understood. Several studies have shown that the
use of cyclodextrins can reduce the apparent perme-
ability of the drug,14–16 an effect that is often
qualitatively attributed to a decrease in the free
fraction of the drug available for membrane permea-
tion. These opposing effects of cyclodextrins on
solubility and permeability can lead to paradoxical
effects on the overall fraction of drug absorbed.
Indeed, a critical review of the literature reveals that
the use of cyclodextrins can result in enhanced,
unchanged, or even decreased oral bioavailabil-
ity.17,18 As a result of these observations, qualitative
guidelines for the proper use of cyclodextrins have
been proposed,14,18,19 however no quantitative ana-
lysis that enables simulation of the overall effect of
cyclodextrins on intestinal membrane permeability is
currently available.
The aims of this research were to develop math-
ematical mass transport models to explain the impact
of molecular complexation with cyclodextrins on
intestinal membrane permeation, and to mechan-
istically elucidate the interplay between the opposing
effects of cyclodextrins on apparent solubility and
permeability. To evaluate the mathematical theory,
the models were applied to the highly lipophilic, low-
solubility, BCS class II drug progesterone,20 utilizing
several in vitro and in situ intestinal membrane
transport models, that is, PAMPA, Caco-2 cell
monolayers, and single-pass rat jejunal perfusion.
Overall, this work provides an increased under-
standing of the underlying mechanisms that govern
the effects of molecular complexation on intestinal
membrane transport, and enables the more efficient
and intelligent use of molecular complexation
strategies to facilitate oral absorption.THEORY
Quasi-Equilibrium Analysis of the Effect of
Cyclodextrins on Membrane Transport
The intrinsic membrane permeability of free drug






where Dm( F) is the membrane diffusion coefficient of
the free drug in the absence of cyclodextrins, Km( F)
the membrane/aqueous partition coefficient of drug in
the absence of cyclodextrins, and hm( F) the membrane
thickness experienced by free drug in the absence of
cyclodextrins.JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 6, JUNE 2010Likewise, the apparent membrane permeability of






where Dm is the apparent membrane diffusion
coefficient of the drug in the presence of cyclodextrins
and Km is the apparent membrane/aqueous
partition coefficient of the drug in the presence of
cyclodextrins.
Assuming only the free drug permeates the
membrane such that Dm( F)¼Dm and that the
presence of cyclodextrins does not effect the mem-
brane thickness such that hm( F)¼hm, Eqs. (1) and (2)














where Sm( F) is the membrane solubility of the free
drug, Saq( F) the aqueous solubility of the free drug, Sm
the apparent membrane solubility of the drug in the
presence of cyclodextrins, and Saq the apparent
aqueous solubility of the drug in the presence of
cyclodextrins.
Assuming that the presence of cyclodextrins does
not affect the drug solubility in the membrane such





Assuming 1:1 complexation between drug and
cyclodextrins, the dependence of drug solubility
on cyclodextrins concentration (CCD) can be written
as:
Saq ¼ SaqðFÞðK11aqCCD þ 1Þ (7)
where K11aq is the aqueous association constant of the
1:1 drug/cyclodextrins complex.














THE SOLUBILITY–PERMEABILITY INTERPLAY IN USING CYCLODEXTRINS 2741Eqs. (8) and (9) can be combined to express the Pm
dependence on F:
Pm ¼ PmðFÞF (10)
The intrinsic permeability of the free drug through
the unstirred aqueous boundary layer (Paq( F)) in the





where Daq( F) is the diffusion coefficient of the free
drug through the unstirred aqueous boundary layer
in the absence of cyclodextrins and haq( F) is the
unstirred aqueous boundary layer thickness experi-
enced by free drug in the absence of cyclodextrins.
Likewise, the apparent unstirred aqueous bound-
ary layer permeability of the drug in the presence of





where Daq is the apparent diffusion coefficient of the
drug through the unstirred aqueous boundary layer
in the presence of cyclodextrins and haq is the
apparent unstirred aqueous boundary layer thick-
ness in the presence of cyclodextrins.





Daq may be expressed as:
22
Daq ¼ FDaqðFÞ þ BDaqðBÞ (14)
where B is the fraction of drug molecules bound
to cyclodextrins (B¼ 1F) and Daq(B) is the aqueous
diffusion coefficient of the drug–cyclodextrin
complex. Since the molecular size of the cyclodextrin
is much larger than that of the free drug, Daq(B)
may be assumed to be approximately equal to the
aqueous diffusion coefficient of free cyclodextrin,
Daq(CD):
DaqðBÞ  DaqðCDÞ (15)
Likewise, haq may be expressed as:
haq ¼ FhaqðFÞ þ BhaqðBÞ (16)
where haq(B) is the apparent unstirred aqueous
boundary layer thickness experienced by the drug–
cyclodextrin complex.
Eqs. (11), (13), (14), and (16) can be combined to





(17)DOI 10.1002/jpsAssuming that the unstirred aqueous boundary
layer is no longer relevant for the drug–cyclodextrin
complex (i.e., haq(B)¼ 0 and haq¼Fhaq( F)), Eqs. (9)






where the dependence of Daq on CCD may be
calculated using Eqs. (14) and (15).
Taking into account the membrane permeability as
well as the unstirred aqueous boundary layer
permeability on either side of the membrane, Paq(1)
and Paq(2), the overall effective permeability (Peff) of
the drug can be written as:22
Peff ¼
1
1=Paqð1Þ þ 1=Pm þ 1=Paqð2Þ
(19)
For simplicity, Paq(2) is assumed to have a negligible






Thus, the overall Peff dependence on CCD may be
predicted via Eq. (20) wherein the Pm and Paq
dependence on CCD are predicted using Eqs. (8)
and (18) with knowledge of Pm( F), K11aq, Paq( F), Daq( F),
and Daq(CD).
Moreover, the drug concentration at the interface
between the UWL and membrane (Caq Membrane Surface)







The assumptions nested in these analyses include:
(1) quasi-equilibrium conditions (2) 1:1 stoichiometry
between drug/cyclodextrin complex; (3) only the
free drug partitions and diffuses into the membrane,
but not the drug/cyclodextrin complex, such that
Sm( F)¼Sm and Dm( F)¼Dm; (4) the presence
of cyclodextrins does not affect the membrane
thickness such that hm( F)¼hm; and (5) only the free
drug encounters a significant unstirred aqueous
boundary layer thickness but the unstirred aqueous
boundary layer thickness is negligible for the drug–
cyclodextrins complex such that haq(B)¼ 0.MATERIALS AND METHODS
Materials
Progesterone, 2-hydroxypropyl-b-cyclodextrins (HPb-
CD), phenol red and hexadecane were purchased fromJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 6, JUNE 2010
2742 DAHAN ET AL.Sigma Chemical Co. (St. Louis, MO). Hexane, potas-
sium chloride, and NaCl were obtained from Fisher
Scientific, Inc. (Pittsburgh, PA). Acetonitrile and water
(Acros Organics, Geel, Belgium) were HPLC grade. All
other chemicals were of analytical reagent grade.
Solubility Studies
The solubility experiments for progesterone with
HPbCD were conducted according to the method
described by Higuchi and Connors.23 To a number of
test tubes containing excess amounts of progesterone,
0–0.015 M aqueous HPbCD solutions were added.
The intrinsic solubility in water was determined from
five individual samples without HPbCD. The test
tubes were tightly closed and placed in a shaking
water bath at 258C and 100 rpm. Establishment of
equilibrium was assured by comparison of samples
after 24 and 48 h. Before sampling, the vials were
centrifuged at 10,000 rpm for 10 min. Supernatant
was carefully withdrawn from each test tube, filtered,
and immediately assayed for drug content by HPLC.
Caco-2 Cell Monolayer Assay
Caco-2 cells (passage 25–32) from American Type
Culture Collection (Rockville, MD) were routinely
maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen Corp., Carlsbad, CA) containing
10% fetal bovine serum, 1% nonessential amino acids,
1 mM sodium pyruvate, and 1% L-glutamine. Cells
were grown in an atmosphere of 5% CO2 and 90%
relative humidity at 378C. The DMEM medium was
routinely replaced by fresh medium every 3 days.
Cells were passaged upon reaching approximately
80% confluence using 4 mL trypsin–EDTA (Invitro-
gen Corp.).
Transepithelial transport studies were performed
using a method described previously.24,25 Briefly,
5 104 cells/cm2 were seeded onto collagen-coated
membranes (12-well Transwell plate, 0.4-mm pore
size, 12 mm diameter, Corning Costar, Cambridge,
MA) and were allowed to grow for 21 days. Mannitol
and Lucifer yellow permeabilities were assayed for
each batch of Caco-2 monolayers (n¼ 3), and TEER
measurements were performed on all monolayers
(Millicell-ERS epithelial Voltohmmeter, Millipore
Co., Bedford, MA). Monolayers with apparent man-
nitol and Lucifer yellow permeability <3 107 cm/s,
and TEER values >300Vcm2 were used for the study.
On the day of the experiment, the DMEM was
removed and the monolayers were rinsed and
incubated for 20 min with a blank transport buffer.
The apical transport buffer contained 1 mM CaCl2,
0.5 mM MgCl26H2O, 145 mM NaCl, 3 mM KCl, 1 mM
NaH2PO4, 5 mM D-glucose, and 5 mM MES, at pH 6.
Following the 20 min incubation, the drug free
transport buffer was removed from the apical side
and replaced by 0.5 mL of progesterone solution in theJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 6, JUNE 2010uptake buffer, with or without HPbCD. Throughout
the experiment, the transport plates were kept in a
shaking incubator (50 rpm) at 378C (unless stated
otherwise). Samples were taken from the receiver
(basolateral) side at various time points up to 120 min
(50mL), and similar volumes of blank buffer were
added following each sample withdrawal. At the last
time point (120 min), sample was taken from the
donor (apical) side as well, in order to confirm mass
balance. Samples were immediately assayed for drug
content. Caco-2 monolayers were checked for con-
fluence by measuring the TEER before and after the
transport study.
Permeability coefficient (Papp) across Caco-2 cell
monolayers was calculated from the linear plot of
drug accumulated in the receiver side versus time,







where dQ/dt is the steady-state appearance rate of the
drug on the receiver side, C0 the initial concentration
of the drug in the donor side, and A the monolayer
growth surface area (1.12 cm2). Linear regression was
carried out to obtain the steady-state appearance rate
of the drug on the receiver side.
Parallel Artificial Membrane Permeation Assay
(PAMPA)
PAMPA studies were carried out using a method
described previously with minor modifications.26,27
Solutions of progesterone (25mM) were prepared with
HPbCD at concentrations of 0, 0.1, 0.2, 0.4, 0.8, and
1.6 mM in phosphate buffer saline (PBS) pH 7.4.
PAMPA experiments were carried out in Millipore
(Danvers, MA) 96-well MultiScreen-Permeability
filter plates with 0.3 cm2 polycarbonate filter support
(0.45mm). The filter supports in each well were first
impregnated with 15mL of a 5% solution (v/v) of
hexadecane in hexanes. The wells were then allowed
to dry for 1 h to ensure complete evaporation of the
hexanes resulting in a uniform layer of hexadecane.
The donor wells were then loaded with 0.15 mL of the
progesterone-HPbCD solution and each receiver well
was loaded with 0.3 mL of PBS. Five wells were
loaded at each HPbCD concentration to enable
collection of a well at times points of 30, 60, 90,
120, and 150 min and each experiment was repeated
three times for a total of 15 wells per HPbCD
concentration. The donor plate was then placed upon
the 96-well receiver plate and the resulting PAMPA
sandwich was incubated at 258C. Receiver plate wells
(n¼ 3 for each HPbCD concentration) were then
collected every 30 min over 2.5 h and the progesterone
concentration in each well was determined by HPLC.
Permeability coefficient (Papp) across Caco-2 cell
monolayers was calculated from the linear plot ofDOI 10.1002/jps
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using Eq. (22).
Rat Jejunal Perfusion
All animal experiments were conducted using proto-
cols approved by the University Committee of Use
and Care of Animals (UCUCA), University of
Michigan, and the animals were housed and handled
according to the University of Michigan Unit for
Laboratory Animal Medicine guidelines. Male albino
Wistar rats (Charles River, IN) weighing 250–300 g
were used for all perfusion studies. Prior to each
experiment, the rats were fasted overnight (12–18 h)
with free access to water. Animals were randomly
assigned to the different experimental groups.
The procedure for the in situ single-pass intestinal
perfusion followed previously published reports.28,29
Briefly, rats were anesthetized with an intramuscu-
lar injection of 1 mL/kg of ketamine–xylazine solution
(9%:1%, respectively) and placed on a heated surface
maintained at 378C (Harvard Apparatus Inc., Hollis-
ton, MA). The abdomen was opened by a midline
incision of 3–4 cm. A 10 cm proximal jejunal segment
was carefully exposed and cannulated on two ends
with flexible PVC tubing (2.29 mm i.d., inlet tube
40 cm, outlet tube 20 cm, Fisher Scientific, Inc.). Care
was taken to avoid disturbance of the circulatory
system, and the exposed segment was kept moist with
378C normal saline solution. Solutions of progester-
one (25mM) were prepared with HPbCD at concen-
trations of 0, 0.025, 0.25, and 2.5 mM in the perfusate
buffer. This buffer consisted of 10 mM MES buffer, pH
6.5, 135 mM NaCl, 5 mM KCl, and 0.1 mg/mL phenol
red, a nonabsorbable marker for measuring water
flux. All perfusate solutions were incubated in a 378C
water bath. The isolated segment was first rinsed
with blank perfusion buffer at a flow rate of 0.5 mL/
min to clean out any residual debris. At the start of
the study, the test solutions were perfused through
the intestinal segment (Watson Marlow Pumps 323S,
Watson-Marlow Bredel, Inc., Wilmington, MA) at a
flow rate of 0.2 mL/min. The perfusion buffer was first
perfused for 1 h, in order to ensure steady state
conditions (as also assessed by the inlet over outlet
concentration ratio of phenol red which approaches 1
at steady state). After reaching steady state, samples
were taken in 10 min intervals for 1 h. All samples,
including perfusion samples at different time points,
original drug solution, and inlet solution taken at the
exit of the syringe were immediately assayed by
HPLC. Following the termination of the experiment,
the length of each perfused jejunal segment was
accurately measured.
The net water flux in the single-pass rat jejunal
perfusion studies, resulting from water absorption in
the intestinal segment, was determined by measure-
ment of phenol red, a nonabsorbed, nonmetabolizedDOI 10.1002/jpsmarker. The measured Cout/Cin ratio was corrected for





 Cin phenol red
Cout phenol red
(23)
where Cin phenol red is the concentration of phenol red
in the inlet sample, and Cout phenol red is the
concentration of phenol red in the outlet sample.
The effective permeability (Peff) through the rat gut
wall in the single-pass intestinal perfusion studies
was determined assuming the ‘‘plug flow’’ model





where Q is the perfusion buffer flow rate, C0out/C
0
in is
the ratio of the outlet concentration and the inlet
concentration of the tested drug that has been
adjusted for water transport via Eq. (23), R is the
radius of the intestinal segment (set to 0.2 cm), and L
is the length of the intestinal segment.
High-Performance Liquid Chromatography (HPLC)
HPLC analyses were performed on an Agilent
Technologies (Palo Alto, CA) HPLC 1100 equipped
with photodiode array detector and ChemStation for
LC 3D software. Progesterone was assayed using an
Agilent Technologies 150 mm 4.6 mm XDB-C18 col-
umn with 5mm particle size. The detection wave-
length was 242 nm. The mobile phase consisted of
30:70 (v/v) 0.1% trifluoroacetic acid in water: 0.1%
trifluoroacetic acid in acetonitrile and was pumped at
a flow rate of 1.0 mL/min. Injection volumes for all
HPLC analyses ranged from 5 to 100mL. Separate
standard curves were used for each experiment
(R2> 0.99).
Statistical Analysis
All in vitro experiments were performed in triplicate
(unless stated otherwise), and all animal experiments
were n¼ 4. Values are expressed as the means
 the
standard deviation (SD). To determine statistically
significant differences among the experimental
groups, the nonparametric Kruskal–Wallis test was
used for multiple comparisons, and the two-tailed
nonparametric Mann–Whitney U-test for two-group
comparison where appropriate. A p-value of less than
0.05 was termed significant.RESULTS
Effect of HPbCD on Progesterone Solubility
The solubility data for complex formation between
progesterone and HPbCD is presented in Figure 1.
Progesterone solubility increased linearly (R2> 0.99)
with increasing HPbCD concentrations as per Eq. (7).JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 6, JUNE 2010
Figure 1. Aqueous solubility of progesterone as a func-
tion of increasing HPbCD concentration at 258C. Data are
presented as means
SD (error bars smaller than symbols);
n¼ 3 in each experimental group.
2744 DAHAN ET AL.The linearity of the phase solubility diagram indi-
cates 1:1 stoichiometric complexation between pro-
gesterone and HPbCD. A very strong binding
constant of 14,324 M1 was calculated from the
solubility data via Eq. (7).
Effect of HPbCD on Progesterone Transport Across
Caco-2 Cell Monolayers
The dependence of progesterone flux across Caco-2
cell monolayer, and the corresponding Papp values, on
HPbCD concentration (0 and 75mM) is presented in
Figure 2. It can be seen that progesterone perme-
ability decreased twofold in the presence of 75mM
HPbCD as compared to progesterone alone. These
data were obtained under a constant rotation speed ofFigure 2. Progesterone (25mM) flux across Caco
of 75mM HPbCD (*) at 50 rpm rotation speed (lef
Data are presented as means
SD; n¼ 3 in each
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 6, JUNE 201050 rpm. To determine whether the results obtained
under this condition represent the true membrane
permeability (Pm( F)) of progesterone, that is, to assess
the effect of the unstirred water layer (UWL),
progesterone Caco-2 permeability was evaluated as
a function of rotation speed (Fig. 3a). Significantly
higher transport was evident with increased rotation
speed from 0, to 20, and to 50 rpm, indicating that
progesterone Papp is limited by the UWL, at low
rotation speeds. Additional increase in rotation speed
to 70 rpm failed to produce increased flux, indicating
that the UWL does not limit the overall Papp at high
rotation speeds. Hence, it is evident that the Papp
value obtained at 50 rpm (4.8 105 cm/s) approxi-
mates the true intrinsic membrane permeability
(Pm( F)) of progesterone across Caco-2 monolayers.
The effect of rotation speed on progesterone
Caco-2 membrane transport was also evaluated
in the presence of 75mM HPbCD. As shown in
Figure 3b, similar progesterone permeabilities were
obtained at different rotation speeds 0–50 rpm,
consistent with the idea that the UWL is no
longer rate limiting and progesterone Papp is under
membrane control at an HPbCD concentration as
low as 75mM. This observation is in corroboration
with previous reports that cyclodextrins may reduce
the UWL effect on the Papp of lipophilic com-
pounds.8,16,31,32
Figure 4 compares the predicted permeability of
progesterone across Caco-2 cell monolayers as a
function of HPbCD concentration to the experi-
mentally observed Papp values. The theoretical
lines were calculated via Eq. (8) (Pm), Eq. (18)
(Paq), and Eq. (20) (Peff) using the experimental
values of Pm( F)¼ 4.8 105 cm/s, K11aq¼ 14,324 M1,-2 monolayers alone (*) and in the presence
t), and the corresponding Papp values (right).
experimental group.
DOI 10.1002/jps
Figure 3. Papp values of progesterone (25mM) across Caco-2 monolayers at different rotation
speeds, in the absence of HPbCD (left; panel a) and in the presence of 75mM HPbCD (right; panel
b). Data are presented as means
SD; n¼ 3 in each experimental group.
THE SOLUBILITY–PERMEABILITY INTERPLAY IN USING CYCLODEXTRINS 2745Daq( F)¼ 8.5 106 cm2/s from Amidon et al.,22 and
Daq(CD)¼ 3.2 106 cm2/s from Ribeiro et al.33 The
value of Paq( F) was calculated to be 10.6 105 cm/s
via Eq. (20) using the experimental Papp value of
3.3 105 cm/s at 0 rpm rotation speed in the absence
of cyclodextrins for Peff, and the experimental Papp
value of 4.8 105 cm/s at 50 rpm rotation speed in
the absence of cyclodextrins for Pm( F). The predicted
values for both Peff and Pm agreed well with the
experimentally observed Papp value of 2.3 105 cm/s
at a cyclodextrins concentration of 75mM (Fig. 4). In
fact, the theoretical value of Pm calculated via Eq. (8)
exactly matched the experimentally observed Papp
value.
Effect of HPbCD on Progesterone Transport in
PAMPA Model
The theoretical and experimental dependence of
progesterone Papp on HPbCD concentration in theFigure 4. Permeability of progesterone across Caco-2 cell
monolayers as a function of HPbCD concentration. The
theoretical lines were calculated via Eq. (8) (Pm), Eq. (18)
(Paq), and Eq. (20) (Peff). Experimental data points are
presented as means
SD; n¼ 3 in each experimental group.
DOI 10.1002/jpshexadecane-based PAMPA model is shown in
Figure 5. Progesterone PAMPA permeability in the
absence of HPbCD was investigated at increasing
rotation speeds as well, in order to assess the effect of
the UWL (Fig. 6). Progesterone permeability
decreased 2.1, 3.5, 6.4, 15.4, and 33.1 times at HPbCD
concentrations of 0.1, 0.2, 0.4, 0.8, and 1.6 mM,
respectively, as compared to progesterone alone
(Fig. 5). It can be seen that progesterone permeability
in the PAMPA model remained constant with
increasing rotation speed up to 100 rpm (Fig. 6). This
indicates that progesterone permeability is under
membrane control in the hexadecane membrane
PAMPA model. Thus, the effect of the UWL does
not need to be considered and Eq. (8) may be directly
applied to predict the dependence of progesterone
apparent membrane permeability on HPbCD con-
centration. Hence, the theoretical progesteroneFigure 5. Papp of progesterone as a function of HPbCD
concentration in the PAMPA assay. The theoretical line was
calculated via Eq. (8) using the experimental values of
Pm¼ 11.0 106 cm/s and K11aq¼ 14,324 M1. Experimen-
tal data points are presented as means
SD; n¼ 3 in each
experimental group.
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Figure 6. Papp of progesterone (25mM) in the PAMPA
model at different rotation speeds (0, 50, and 100 rpm). Data
are presented as means
SD; n¼ 3 in each experimental
group.
2746 DAHAN ET AL.PAMPA permeability as a function of HPbCD
concentration illustrated in Figure 5 was calculated
via Eq. (8) using the experimental values of
Pm( F)¼ 11 106 cm/s and K11aq¼ 14,324 M1. Excel-
lent agreement between the experimental data and
the predicted values was obtained at all of the HPbCD
concentrations tested (Fig. 5).
Effect of HPbCD on Progesterone Rat
Jejunal Permeability
The theoretical and experimental progesterone per-
meability in the single-pass intestinal-perfusion rat
model with increasing HPbCD concentrations (0,
0.025, 0.25, and 2.5 mM) is illustrated in Figure 7. In
the absence of HPbCD, progesterone showed very
high permeability (82.4 105 cm/s) across rat jeju-
num. The addition of an equi-molar (25mM) amount
of HPbCD resulted in no significant increase in PeffFigure 7. The effective permeability of progesterone as a
function of HPbCD concentration in the in situ rat jejunal
perfusion model. The theoretical lines were calculated via
Eq. (8) (Pm), Eq. (18) (Paq), and Eq. (20) (Peff). Experimental
data points are presented as means
SD; n¼ 4 in each
experimental group.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 6, JUNE 2010(84.8 105 cm/s). However, the Peff of progesterone
decreased 1.8-fold in the presence of 0.25 mM HPbCD
and 7.8-fold in the presence of 2.5 mM HPbCD.
The predicted lines for Pm, Paq, and Peff in Figure 7
were calculated via Eqs. (8), (18) and (20), respec-
tively. The experimental parameters used in the
calculations were K11aq¼ 14,324 M1 (from this
work), Daq( F)¼ 8.5 106 cm2/s,22 and Daq(CD)¼ 3.2
106 cm2/s.33 The experimental value for progester-
one rat jejunal Pm( F) of 250 105 cm/s used in the
calculations was previously estimated by determining
the Peff of progesterone at increasing perfusate flow
rates.34 The value of Paq( F) used in the predictions
was calculated according to Eq. (20) from the
experimental values of Pm(F) and the Peff of proges-
terone determined in the absence of cyclodextrins
(82.4 105 cm/s). Excellent agreement was obtained
between the experimental and predicted progester-
one Peff values at all of the HPbCD concentrations
tested.
Figure 8 contains the predicted Daq, haq, and Paq as
a function of HPbCD concentration for progesterone
in the rat jejunal perfusion model. The theoretical
curves were calculated according to Eqs. (14)–(18).
The value of haq( F) was calculated to be 103mm via
Eq. (12) using the Peff of progesterone determined in
the absence of cyclodextrins (82.4 105 cm/s) and
the progesterone Daq( F)¼ 8.5 106 cm2/s from Ami-
don et al.22 Figure 9 shows the theoretical membrane
surface to bulk concentration ratio (Caq Membrane
Surface/Caq Bulk) of progesterone as a function of
HPbCD concentration in the rat jejunal perfusion
model. The predicted curve was calculated via
Eq. (21). Figure 10 illustrates the effect of HPbCD
on progesterone aqueous solubility and permeability
based on the theoretical quasi-equilibrium transport
analysis developed in this work. The apparent
solubility and permeability as a function of HPbCDFigure 8. Dependence of Daq, haq, and Paq on HPbCD
concentration for progesterone in the rat jejunal perfusion
model. The theoretical lines were calculated according to
Eqs. (14)–(18).
DOI 10.1002/jps
Figure 9. Theoretical membrane surface to bulk concen-
tration ratio (Caq Membrane Surface/Caq Bulk) of progesterone as
a function of HPbCD concentration in the rat jejunal perfu-
sion model, calculated according to Eq. (21).
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and (20), respectively.DISCUSSION
The trade-off between the apparent solubility
increase and permeability decrease when using
cyclodextrins as pharmaceutical solubilizers is
described in this article. These opposing effects of
cyclodextrin can lead to paradoxical effects on the
overall fraction of drug absorbed. In this work, we
offer a quantitative modeling of the interplay between
the opposing effects of cyclodextrins on the apparent
solubility and permeability, and show the excellent
prediction of overall fraction of drug absorbed as a
function of CCD obtained by the model.
The very strong molecular complexation between
progesterone and HPbCD, as evidenced by theFigure 10. The effect of HPbCD on progesterone solubi-
lity (gray) and permeability (black) based on the theoretical
quasi-equilibrium transport analysis. Solubility and perme-
ability were calculated using Eqs. (7) and (20), respectively.
DOI 10.1002/jpsextremely high binding constant of 14,324 M1,
results in substantially enhanced aqueous solubility
(Fig. 1). Indeed, this solubility advantage provided by
cyclodextrins is the primary reason for their wide-
spread popularity and use. The high binding constant
also results in very little free progesterone, even at
relatively low HPbCD concentrations. For example,
the free fraction of progesterone is 0.5 at an HPbCD
concentration of only 70mM, and at HPbCD concen-
trations of >1.4 mM, the free fraction of progesterone
is <0.05. This decreased fraction of free drug can
significantly alter membrane permeation behavior as
was observed in this work using the PAMPA, Caco-2
cell monolayers, and in situ rat jejunal perfusion
models.
In the Caco-2 studies, progesterone permeability
decreased twofold in the presence of 75mM HPbCD
(Figs. 2 and 3), as compared to progesterone alone. In
the absence of cyclodextrin, significantly higher
permeabilities were observed with increased rotation
speed from 0, to 20, and to 50 rpm, indicating that
progesterone Papp is limited by the UWL at low
rotation speeds (Fig. 3a). This observation is in
corroboration with previous reports.22,34–36 An addi-
tional increase in rotation speed to 70 rpm failed to
produce increased flux, indicating that in this
experimental method, the UWL does not limit the
overall Papp at rotation speeds of 50 rpm and above
(Fig. 3a). Hence, it is evident that the Papp value
obtained at 50 rpm (4.8 105 cm/s) approximates the
true membrane permeability (Pm(F)) of progesterone
across Caco-2 monolayers. In the presence of cyclo-
dextrins, progesterone permeability was no longer
limited by the UWL, as evidenced by the lack of
rotation speed effect (Fig. 3b). This is in agreement
with previous reports showing that cyclodextrins may
reduce the UWL effect on the Papp of lipophilic
compounds.8,16,31,32 Since progesterone Caco-2 per-
meability is under membrane control at an HPbCD
concentration as low as 75mM and 50 rpm stir speed,
it follows that the predicted Pm (Eq. 8) exactly
matches the experimentally observed Papp value at
75mM HPbCD (Fig. 4).
Progesterone permeability was also significantly
impacted by the presence of HPbCD in the hexade-
cane-based PAMPA model (Fig. 5). The overall
transport was unaffected by rotation speed (Fig. 6),
indicating that in this experimental model progester-
one permeability is not significantly effected by the
UWL, rather the rate of transport across the
hexadecane membrane is rate limiting. This is not
to say that the UWL is not present in the PAMPA
model, rather the effect of the UWL on overall
permeability is insignificant as compared to the
hexadecane membrane. Hence, the Papp in the
absence of HPbCD can be assumed to be approxi-
mately equal to Pm(F) and only the effect of HPbCD onJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 6, JUNE 2010
2748 DAHAN ET AL.Pm (Eq. 8) needs to be considered (i.e., PeffPm).
Indeed, excellent agreement was achieved between
the experimental and predicted permeability of
progesterone as a function of HPbCD concentration
in the PAMPA model when Eq. (8) was used for the
predictions (Fig. 5).
Progesterone permeability across rat jejunal seg-
ments was also significantly altered by the presence
of cyclodextrins. As shown in Figure 7, the progester-
one Peff across the rat jejunum stayed relatively
consistent at very low HPbCD concentrations
(0.025 mM), but then decreased rapidly with increas-
ing cyclodextrins concentration (0.25–2.5 mM). This
results because at very low cyclodextrins concentra-
tions, the overall Peff is limited by the UWL. This is in
corroboration with previous reports that have shown
progesterone permeability to be limited by the
aqueous boundary layer in the rat intestinal perfu-
sion model.34,35 As shown in Figures 9 and 10, the
predicted Paq increases markedly with increasing
cyclodextrins concentration. This may be explained
by the high value of K11aq, as the UWL is only
experienced by the free drug and is effectively
eliminated for the progesterone-HPbCD complex
(i.e., haq(B)¼ 0), such that the effective thickness of
the boundary layer decreases with decreasing free
fraction (i.e., haq¼Fhaq( F)). This is in agreement with
and explains some previous reports showing that
cyclodextrins may reduce the UWL effect on the
apparent permeability of lipophilic com-
pounds.8,16,31,32 Figure 8 shows the predicted Daq,
haq, and Paq dependence on HPbCD concentration,
calculated via Eqs. (14)–(18). The value of progester-
one Daq decreases with increasing cyclodextrins
concentration, which does contribute to a slight
decrease in the overall value of Paq as expressed in
Eqs. (12) and (18). However, this effect is essentially
negligible in comparison to the effect of the shrinking
haq, which leads to a marked increase in Paq with
increasing HPbCD concentration (Fig. 8). As shown
in Figure 9, the shrinking UWL with increasing
HPbCD concentration also causes the progesterone
concentration at the surface of the membrane to
increase and eventually become equal to the proges-
terone concentration in the bulk as the concentration
of HPbCD increases. In this way, complexation with
cyclodextrins effectively shorts out the UWL by
facilitating the transport of drug to the membrane
surface such that Caq Membrane SurfaceCaq Bulk, and
permeation across the intestinal membrane becomes
rate limiting.22 At the same time, Pm decreases
rapidly with increasing cyclodextrin concentration
(Fig. 7). This may also be attributed to the high
binding constant between progesterone and HPbCD,
which causes the amount of free drug available for
membrane permeation to decrease rapidly with
increasing cyclodextrins concentration, as describedJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 6, JUNE 2010in Eqs. (8) and (10). Figure 7 contains the overall
predicted Peff as a function of cyclodextrins concen-
tration in the rat intestinal perfusion model. The
predicted Peff was calculated via Eq. (20). Excellent
agreement was obtained between the experimental
and predicted progesterone Peff values at all of the
HPbCD concentrations tested. The overall Peff stays
relatively constant at very low HPbCD concentra-
tions, but then decreases rapidly with increasing
cyclodextrin concentration. This results because
at very low cyclodextrin concentrations, the overall
Peff is limited by the UWL. However, the rapidly
decreasing effective haq with increasing HPbCD
concentration causes Paq to markedly increase, such
the UWL is quickly eliminated and the overall Peff
becomes membrane controlled at higher HPbCD
concentrations. This is evidenced by the fact that
the experimental and predicted values of Peff are
essentially equal to the predicted values of Pm at the
higher HPbCD concentrations of 0.25 and 2.5 mM
(Fig. 7). It is acknowledged that validation of any
mathematical model is a continuous process, and
additional data would be of benefit.
It should be emphasized that the shrinking
effective haq results directly from the decrease in
free fraction of drug with increasing cyclodextrins
concentration. Indeed, the UWL thickness experi-
enced by the free drug remains constant with
increasing cyclodextrins concentration. However,
since the free fraction of drug decreases with
increasing cyclodextrin concentration and it is
assumed that the drug–cyclodextrin complex does
not experience a UWL thickness (i.e., haq(B)¼ 0), the
overall effective UWL thickness decreased as bound
fraction increases and free fraction decreases (i.e.,
haq¼Fhaq( F)). As stated in the model assumptions,
this model does not consider cases in which interac-
tion between the free cyclodextrin and the membrane
exists.CONCLUSIONS
In conclusion, this work demonstrates that when
using cyclodextrins as pharmaceutical solubilizers, a
trade-off exists between solubility increase and
permeability decrease that governs the overall
fraction of drug absorbed. Given these opposing
effects, both apparent solubility and permeability
considerations must be taken into account, to strike
the appropriate balance in order to achieve optimal
absorption from a cyclodextrin-based formulation.
The quasi-equilibrium mass transport analysis devel-
oped in this work could successfully predict the Peff
dependence on HPbCD concentration with knowl-
edge of K11aq, Pm(F), Paq( F) and the aqueous diffusion
coefficients of the free drug and cyclodextrins, Daq( F)DOI 10.1002/jps
THE SOLUBILITY–PERMEABILITY INTERPLAY IN USING CYCLODEXTRINS 2749and Daq(CD). Knowledge of the solubility–permeability
interplay and the dependence of these parameters on
cyclodextrin concentration enables the more efficient
and intelligent use of cyclodextrins in oral drug
product formulation development.REFERENCES
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